News Releases

First and only non-coated sirolimus-eluting angioplasty balloon system to show promising clinical results Potential to offer significant advantages for treatment of coronary in-stent restenosis (ISR), a condition that represents over 10% of total interventional procedures New Hope, PA – Orchestra

Panel presentation will provide an overview and outlook on BackBeat Cardiac Neuromodulation Therapy, a potent, novel bioelectronic treatment for hypertension Hypertension, considered the #1 contributing risk factor for death by WHO, is a global epidemic that affects over 100 million Americans and

- Presentation with live audio webcast on Tuesday, March 19, 2019 at 3:20 p.m. ET - Webcast Link:  https://www.veracast.com/webcasts/opco/healthcare2019/82115698694.cfm New Hope, PA – Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company developing advanced

New Hope, PA – Orchestra BioMed, Inc., (“Orchestra BioMed” or the “Company”), a biomedical innovation company developing advanced therapeutic solutions to address major unmet medical needs, today announced that David Hochman, Chairman and Chief Executive Officer, will present a corporate overview

Event:  Piper Jaffray Healthcare Conference Date:  Thursday, November 29, 2018 at 9:30 a.m. EST Webcast Link:   https://event.webcasts.com/starthere.jsp?ei=1222275&tp_key=5bdf221dd0

Capital proceeds to support late-stage clinical development of lead cardiovascular product candidates for artery disease and hypertension Financing structure provides for up to an additional $23 million in follow-on financing from existing investors New Hope, PA – Orchestra BioMed, Inc.,

Novel Treatment Delivers Immediate, Substantial, and Sustained Reduction in Blood Pressure Potential to Become a Broadly Applicable Therapy for Device-Based Hypertension Management New Hope, PA – Orchestra BioMed, Inc., (“Orchestra BioMed” or the “Company”), a biomedical innovation company

Ron Dadino appointed Vice President, Pharmaceutical Development & Operations, Cardiovascular Interventions Greg Kopia, Ph.D., CMPP appointed Director, Pre-Clinical Development, Cardiovascular Interventions Ziv Belsky appointed Vice President, Research & Development, Cardiac Neuromodulation New

Eric A. Rose, M.D., biotech and medical device business leader as well as world-renowned cardiac surgeon and scientist who performed the landmark achievement of the first successful pediatric heart transplant Jason Aryeh, life sciences industry expert, investment fund manager, and Director of

Ms. Wheeler brings an extensive track record in marketing, strategy and commercial program development New Hope, PA – Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company developing high impact, high value, evidence-based therapeutic solutions for medical